Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

Table 3 Variables associated with overall survival

Variables	Univariate		Multivariate
	HR(95%CI)	P value	HR(95%CI)	P value
Gender, male (vs female)	0.384 (0.147-1.005)	0.051
Age, ≤ 70 yr (vs > 70 yr)	0.491 (0.225-1.071)	0.074	0.354 (0.135-0.933)	0.036
Previous therapy yes (vs no)	0.035 (0.128-0.961)	0.042
DCP, ≤ 1000 mAU/mL (vs > 1000 mAU/mL)	0.416 (0.178-0.974)	0.043
Initial dose of sorafenib, 800 mg (vs < 800 mg)	0.405 (0.185-0.888)	0.024
Adverse events > grade 2
Anorexia - (vs +)	0.374 (0.158-0.888)	0.026
Skin toxicitya + (vs -)	0.278 (0.122-0.635)	0.002	0.267 (0.102-0.701)	0.007
Fatigue - (vs +)	0.404 (0.176-0.924)	0.032
Hypoalbuminemia - (vs +)	0.379 (0.170-0.842)	0.017	0.221 (0.085-0.575)	0.002

^aSkin toxicity includes hand–foot skin reaction and any kind of rash. HR: Hazard ratio; DCP: Des-gamma-carboxy prothrombin. This table only includes variables with P values < 0.15 in univariate analyses.